Food and Drug Administration

Oncologic Drugs Advisory Committee

March 13, 2003



The statements contained in this document(s) are those of the product's sponsor, not FDA, and FDA does not necessarily agree with the sponsor's statements. FDA has not made a final determination about the safety or effectiveness of the product described in this document.

Mylotarg® (gemtuzumab ozogamicin), Wyeth (PDF)

DepoCyte® (cytarabine liposome injection), Skyepharma, Inc. (HTM) (PPT)

Celecoxib (CELEBREX®) Familial Adenomatous Polyposis (FAP), Dr. Daniel Vlock, MD, Pharmacia (HTM) (PPT)

Temozolomide, Schering-Plough Research Institute (HTM) (PPT)